Metrizamide

Identification

Name
Metrizamide
Accession Number
DB01578
Type
Small Molecule
Groups
Approved
Description

Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.

Structure
Thumb
Synonyms
Not Available
External IDs
WIN 39103 / WIN-39103
International/Other Brands
Amipaque
Categories
UNII
RHH3W8F1CO
CAS number
31112-62-6
Weight
Average: 789.1
Monoisotopic: 788.8541
Chemical Formula
C18H22I3N3O8
InChI Key
DTZMSDADRKLCQE-RFMXWLSYSA-N
InChI
InChI=1S/C18H22I3N3O8/c1-6(27)22-14-11(19)10(12(20)15(13(14)21)24(3)7(2)28)18(32)23-8(4-25)16(30)17(31)9(29)5-26/h4,8-9,16-17,26,29-31H,5H2,1-3H3,(H,22,27)(H,23,32)/t8-,9+,16+,17+/m0/s1
IUPAC Name
3-[(1-hydroxyethylidene)amino]-2,4,6-triiodo-5-(N-methylacetamido)-N-[(2R,3R,4S,5R)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]benzene-1-carboximidic acid
SMILES
[H][[email protected]@](O)(CO)[[email protected]@]([H])(O)[[email protected]]([H])(O)[[email protected]]([H])(C=O)N=C(O)C1=C(I)C(N=C(C)O)=C(I)C(N(C)C(C)=O)=C1I

Pharmacology

Indication

Metrizamide is used for lumbar, thoracic, cervical, and total columnar myelography to determine the presence of abnormalities in the spinal column, spinal canal, and central nervous system (CNS) as well as for cisternography by direct injection using standard radiologic techniques to visualize the basal cistern of the brain. For computerized tomography (CT) of the intracranial subarachnoid spaces and for ventriculography by direct injection using standard radiologic techniques to visualize the cerebral ventricles. Also used in pediatric angiocardiography to visualize lesions or malformations of the heart and obstructions or anomalies of the major thoracic vessels. Also used in adult peripheral arteriography to visualize specific regions of the vascular system and blood flow in such areas to help in the diagnosis and evaluation of neoplasms (known or suspected) or vascular diseases (congenital or acquired) that may cause changes in normal vascular anatomy or physiology. Metrizamide is also indicated in adults for intravenous digital arteriography of head and neck.

Structured Indications
Not Available
Pharmacodynamics

Metrizamide is a radiocontrast agent used to improve the contrast of internal body structures using different imaging techniques such as computed tomography scans (CT) or radiography (X-ray imaging).

Mechanism of action

Organic iodine compounds such as metrizamide block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intrathecal administration into the subarachnoid space, diffusion of metrizamide in the CSF allows the visualization of the subarachnoid spaces of the head and spinal canal. After intravascular administration, metrizamide makes opaque those vessels in its path of flow, allowing visualization of the internal structures until significant hemodilution occurs. Metrazamide also has some toxic effects which are thought to be due to its ability to inhibit glucose metabolism.

Absorption

Absorption from gastrointestinal tract is negligible following oral or rectal administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Non-ionic radiocontrast agents like metrizamide are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Experimental, Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Metrizamide.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Metrizamide.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Withdrawn
AlcuroniumMetrizamide may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidMetrizamide may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Metrizamide can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmoxicillinThe serum concentration of Metrizamide can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Metrizamide.Approved, Investigational
AmpicillinThe serum concentration of Metrizamide can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Metrizamide can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumMetrizamide may increase the respiratory depressant activities of Atracurium.Experimental, Investigational
Atracurium besylateMetrizamide may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Metrizamide can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Metrizamide can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Metrizamide can be decreased when it is combined with Bacampicillin.Approved, Investigational
BalsalazideBalsalazide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
BendazacBendazac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Metrizamide can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzydamineBenzydamine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
BenzylpenicillinThe serum concentration of Metrizamide can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Metrizamide can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
Botulinum Toxin Type AMetrizamide may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BMetrizamide may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Metrizamide.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Metrizamide.Approved
CarbenicillinThe serum concentration of Metrizamide can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Metrizamide can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinMetrizamide may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Metrizamide can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
CisatracuriumMetrizamide may increase the respiratory depressant activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateMetrizamide may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Metrizamide.Approved
Clodronic AcidMetrizamide may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Metrizamide can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateMetrizamide may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Metrizamide can be decreased when it is combined with Cyclacillin.Approved
CyclosporineMetrizamide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Metrizamide.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
DecamethoniumMetrizamide may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Metrizamide.Approved
DiclofenacDiclofenac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Metrizamide can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Metrizamide.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Metrizamide.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Metrizamide.Approved
Domoic AcidMetrizamide may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideMetrizamide may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Metrizamide can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metrizamide.Approved
EtanerceptEtanercept may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
Etidronic acidMetrizamide may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
EtoricoxibEtoricoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
exisulindexisulind may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Metrizamide can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunixinFlunixin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Metrizamide.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Metrizamide.Approved, Vet Approved
GallamineMetrizamide may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideMetrizamide may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Metrizamide.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
IbandronateMetrizamide may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Metrizamide.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Metrizamide.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
MecamylamineMetrizamide may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational, Withdrawn
MetampicillinThe serum concentration of Metrizamide can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Metrizamide can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Metrizamide.Experimental
MetocurineMetrizamide may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideMetrizamide may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Metrizamide can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumMetrizamide may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Metrizamide can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinMetrizamide may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Metrizamide.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Metrizamide which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Metrizamide.Approved
OxacillinThe serum concentration of Metrizamide can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Withdrawn
PamidronateMetrizamide may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumMetrizamide may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Metrizamide can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Metrizamide can be decreased when it is combined with Penimepicycline.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Metrizamide.Experimental
PhenoxymethylpenicillinThe serum concentration of Metrizamide can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
PipecuroniumMetrizamide may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Metrizamide can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Metrizamide.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Metrizamide can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Metrizamide can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Metrizamide can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Metrizamide can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Metrizamide.Experimental
PTC299PTC299 may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
PyrantelMetrizamide may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumMetrizamide may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateMetrizamide may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumMetrizamide may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
SuccinylcholineMetrizamide may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Metrizamide can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Metrizamide can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Metrizamide can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Metrizamide can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Metrizamide can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateMetrizamide may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateMetrizamide may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Metrizamide can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Metrizamide can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidMetrizamide may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Metrizamide.Approved
TranilastTranilast may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Metrizamide which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational
TubocurarineMetrizamide may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Metrizamide.Approved
VecuroniumMetrizamide may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational
ZileutonZileuton may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidMetrizamide may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

General References
  1. Azuma H, Nomura S, Ikoma Y, Yokoyama M, Oshino N: A possible mechanism for the neural adverse reactions caused by metrizamide. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd. 1989;128:134-42. [PubMed:2568781]
  2. Ekholm SE, Reece K, Coleman JR, Kido DK, Fischer HW: Metrizamide--a potential in vivo inhibitor of glucose metabolism. Radiology. 1983 Apr;147(1):119-21. [PubMed:6828715]
External Links
PubChem Compound
20056604
PubChem Substance
46506223
ChemSpider
16739315
ChEMBL
CHEMBL1200889
PharmGKB
PA164742936
ATC Codes
V08AB01 — Metrizamide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)223 dec °CPhysProp
water solubility5E+005 mg/L (at 25 °C)MERCK INDEX (1996)
logP-1.89HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0911 mg/mLALOGPS
logP-0.4ALOGPS
logP0.67ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)4.5ChemAxon
pKa (Strongest Basic)-0.18ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area183.48 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity143.32 m3·mol-1ChemAxon
Polarizability56.3 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9938
Blood Brain Barrier-0.9376
Caco-2 permeable-0.6755
P-glycoprotein substrateNon-substrate0.624
P-glycoprotein inhibitor INon-inhibitor0.6859
P-glycoprotein inhibitor IINon-inhibitor0.7024
Renal organic cation transporterNon-inhibitor0.9491
CYP450 2C9 substrateNon-substrate0.6989
CYP450 2D6 substrateNon-substrate0.8594
CYP450 3A4 substrateSubstrate0.5506
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8116
Ames testNon AMES toxic0.7685
CarcinogenicityNon-carcinogens0.8852
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.6272 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9949
hERG inhibition (predictor II)Non-inhibitor0.7864
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Acylaminobenzoic acid and derivatives
Alternative Parents
Hexoses / O-haloacetanilides / P-haloacetanilides / 2-halobenzoic acids and derivatives / 4-halobenzoic acids and derivatives / Benzamides / N-acetylarylamines / Benzoyl derivatives / Iodobenzenes / Aminosaccharides
show 13 more
Substituents
Acylaminobenzoic acid or derivatives / Hexose monosaccharide / O-haloacetanilide / P-haloacetanilide / Haloacetanilide / Acetanilide / 4-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / 2-halobenzoic acid or derivatives / N-acetylarylamine
show 33 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on August 29, 2007 08:52 / Updated on December 01, 2017 14:45